Loading clinical trials...

TERMINATED

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Multicenter, Prospective Epidemiologic Study of The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02479386•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 48 months. There is a planned interim analysis around the 2-year time window for the study.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year for at least 30 days after the last fluorescein dye administration
•The study is being conducted in participants with GA in both Study Eye and Non-Study Eye (bilateral GA) with no evidence of prior or active choroidal neovascularization (CNV)

Exclusion Criteria

•Previous participation in any studies of investigational drugs for GA or dry AMD (except for studies of vitamins and minerals)
•GA in either eye due to causes other than AMD
•History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD
•Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy
•Any ocular or systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments
•Requirement for continuous use of therapy indicated in Prohibited Therapy in the study Protocol

Locations (91)

Northwest Arkansas Retina Associates

Springdale, Arkansas, United States

Retinal Diagnostic Center

Campbell, California, United States

Specialty Eye Care Medical Center

Glendale, California, United States

Jules Stein Eye Institute/ UCLA

Los Angeles, California, United States

East Bay Retina Consultants

Oakland, California, United States

Colorado Retina Associates, PC

Golden, Colorado, United States

Rand Eye

Deerfield Beach, Florida, United States

Bascom Palmer Eye Institute

Naples, Florida, United States

Center For Sight

Sarasota, Florida, United States

Rush University Medical Center

Chicago, Illinois, United States

Key Dates

Start Date

June 24, 2015

Primary Completion Date

April 14, 2017

Completion Date

January 31, 2018

Last Updated

August 20, 2019

Enrollment

296

ACTUAL participants

Conditions

Geographic Atrophy

Interventions

No intervention

OTHER

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

Geographic AtrophyMacular Degeneration

View study

RECRUITINGPHASE2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269

Geographic Atrophy Secondary to Age-related Macular Degeneration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 20, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Inclusion Criteria

Exclusion Criteria

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy